Skip to search formSkip to main contentSkip to account menu

BMS 232632

Known as: 232632, BMS, BMS-232632, BMS232632 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (2)

AtazanavirAtazanavir sulfate
CGP 73547CGP 75136CGP 75176CGP 75355

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction.
2003
2003
Liquid chromatography-tandem mass spectrometric quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human peripheral blood mononuclear cells (PBMC): practical…
Highly Cited
2002
Highly Cited
2002
In Vitro Antiviral Interaction of Lopinavir with Other Protease Inhibitors
ABSTRACT The in vitro inhibition of wild-type human immunodeficiency virus (HIV) by combinations of lopinavir and six other… 
2002
2002
Utilisation d'atazanavir en therapie vih
L'invention concerne un procede de reduction de taux plasmatiques eleves de LDL et/ou de triglycerides chez un patient infecte… 
2001
2001
BMS-232632 (Novartis/Bristol-Myers Squibb).
BMS-232632, an azapeptide HIV protease inhibitor, is in development by Bristol-Myers Squibb (BMS), under license from Novartis… 
Highly Cited
2000
Highly Cited
2000
In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632
ABSTRACT BMS-232632 is an azapeptide human immunodeficiency virus (HIV) type 1 (HIV-1) protease inhibitor that displays potent… 
2000
2000
A preliminary pharmacokinetic and pharmacodynamic evaluation of the HIV protease inhibitor BMS-232632 in a protease inhibitor-naive HIV+ population
2000
2000
BMS-232632, a new protease inhibitor, is taken once daily.
2000
2000
TDM: the key to more effective HIV treatment?
At the 5th International Congress on Drug Therapy in HIV Infection, held in Glasgow, Scotland, October 22-26, 2000, the… 
1999
1999
BMS-232632 : ANTI-HIV HIV-1 PROTEASE INHIBITOR
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)